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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
















Bulletin WHO | 
Article  
 Cross-sectional study of 45 
HICs and 42 non-HICs using 
global burden of disease 
data  
 Whilst in HICs C19 mortality 
was associated with pre-
existing disease burden, no 
association was found 
between disease burdens 
















 It is likely that 40 to 45% of 
those infected with SARS-
CoV-2 will remain 









may silently spread more 
than previously estimated 
 Asymptomatic persons can 
transmit SARS-CoV-2 and 
perhaps longer than 14 
days 
 Absence of symptoms in 
infected persons might not 
imply absence of harm. 
More research is needed to 
determine the significance 
of subclinical lung changes 
 Testing programmes must 
broaden to include those 
without symptoms 
 Limitation – most data 
under review was from 
cohort studies 































 The effectiveness of 3 
distancing strategies 
designed to keep the 
curve flat and aid 
compliance post-
lockdown are evaluated 
in this study 
 Strategic social 
network-based 
reduction of contact 
strongly enhances the 
effectiveness of social 
distancing measures 




















 Control measures 
implemented in Hong 
Kong and Hubei 
province successfully 
restricted the spread of 
SARS-CoV-2 as of May 
2020 
 Relatively low 
seroprevalence 
suggests lack of herd 
immunity and 
susceptibility to a 
resurgence of the 
SARS-CoV-2 epidemic 
if public health 
measures are relaxed 
 Although a small study 
size, provides a 
baseline for public 
health authorities when 
evaluating the effect of 
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NEJM | Article 
 A randomised, 
double-blind, 
placebo-controlled 
trial across the US 






did not prevent 
illness compatible 
with C19 or 
confirmed infection 
when used within 4 
days after high-risk 
or moderate-risk 





03.06.2020 Effect of 
convalescent 
plasma therapy on 








JAMA | Article 
 In this randomised 
clinical trial of 103 
patients in China 








added to standard 
treatment did not 
significantly 







Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
03.06.2020 Hydroxychloroquine for the 
prevention of COVID-19 – 
searching for evidence 







03.06.2020 Africa’s COVID-19 resilience 
must not lead to complacency 
Chatham House | Comment Dr Knox Chitiyo 
Prof Martin Rupiya 
Pamela Wadi 
03.06.2020 A randomised trial of 
convalescent plasma for COVID-
19 – potentially hopeful signals 
JAMA | Editorial  
5 
03.06.2020 Population serology for SARS-
CoV-2 is essential to regional and 
global preparedness 
The Lancet Microbe | 
Comment 
Huaiyu Tian 
Ottar N Bjornstad 
02.06.2020 Global outbreak research: 
harmony not hegemony 





02.06.2020 COVID-19 and essential 
pregnant worker policies 




02.06.2020 Of viruses, vaccines, and 
variability: qualitative meaning 
matters  
Trends in Cognitive Sciences Valerie F. Reyna 
28.05.2020 Covid-19 in humanitarian 
settings: addressing ethics to 
reduce moral distress 
BMJ | Opinion  
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  Sierra 
Leone 





US NIH  Our World in 
Data: C19 
Testing 




Our World in 
Data 






      
Global 5050 













       UKCDR       
Information 
is Beautiful 
              
LSHTM               
HealthMap 
(cases) 




              
  
7 
C19 Resource Hubs 






















LSTM Stop TB 
Partnership 
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ICL MRC Centre for Global 
















ng in low 
resource 
settings 












Johns Hopkins University RBM 
Partnership 









Center for Global 
Development 




UN Women Africa 
Evidence 
Network 






Norwegian Institute of 
Public Health 












Oxford Centre for 
Evidence-based Medicine 
    





 HEART     
UNESCO   NEJM  UKRI     
UN WFP   Oxford 
Universit
y Press 
 Evidence Aid     
GOARN   PLoS  NIH     
EPI-WIN   SAGE 
journals 
IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   Science  Prevent Epidemics      
Our World in 
Data 
  Springer 
Nature 
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(Preprint
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WorldPop           
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Online learning & events 









Online course 1 hour WHO 
16.06.2020 Africa beyond COVID-
19 
Virtual event 1h 30 
hours 
ODI 
15.06.2020 Poverty monitoring in 
the context of Covid-
19 




Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 






on COVID-19 and 
Development: John 
Nkengasong 
Event   CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




















5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative for 










online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 





























the Novel Coronavirus 
Online 
learning 



































FutureLearn University of 
Edinburgh & Royal 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
© DFID - Crown copyright 2020. 
 
